Currently, Indian anti-obesity drug market is bifurcated into prescription and non-prescription. Amongst the prescription anti-obesity drug market there is only one drug – Orlistat that is been used globally. While the other anti-obesity drugs, Rimonabant and Sibutramine were banned by Indian government in 2009 and 2010 as side-effects were found in those drugs.
According to the experts, the market size of anti-obesity for prescription drug (generic Orlistat) is Rs 40 crore. While market size of non-prescription drug mostly herbal and ayurvedic drugs is estimated at Rs 500 crore in India. The global anti-obesity drug market is expected to reach $11 billion by 2017.
Orlistat is originally made by multinational drug company Roche that markets the prescription drug under the brand/trade name Xenical. The drug’s patent protection ended in 2009. Currently, there is plethora of generic drug makers like Ranbaxy, Intas Pharma, Biocon Ltd, Torrent Pharma, Troikaa Pharma and…
View original post 3,622 more words